Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Genitourinary 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 7pembrolizumab 6olaparib 5Carboplatin 4Bevacizumab 4tisotumab vedotin 2niraparib 2mirvetuximab soravtansine 2durvalumab 2defactinib 2Topotecan 2Taxes 2Saline Solution 2Immunoglobulin G 2Disulfides 2Cisplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sodium thiosulfate 1sapanisertib 1sacituzumab govitecan 1rucaparib 1relatlimab 1relacorilant 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1liposomal doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Saline Solution × Gynecologic × Clear all
NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03635567 2026-02-04

KEYNOTE-826

Merck Sharp & Dohme LLC

Phase 3 Completed
617 enrolled 29 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡